In particular, the phase I clinical trial NCT03182816 evaluated the safety and feasibility of piggyBac-generated EGFR-targeted CAR-T cells in patients with advanced, relapsed/refractory EGFR-positive NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.